11.21
2.47%
+0.27
Zynex Inc stock is currently priced at $11.21, with a 24-hour trading volume of 112.90K.
It has seen a +2.47% increased in the last 24 hours and a -9.23% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $11.02 pivot point. If it approaches the $11.36 resistance level, significant changes may occur.
Previous Close:
$10.94
Open:
$10.97
24h Volume:
112.90K
Market Cap:
$357.93M
Revenue:
$184.32M
Net Income/Loss:
$9.73M
P/E Ratio:
24.37
EPS:
0.46
Net Cash Flow:
$16.55M
1W Performance:
-1.49%
1M Performance:
-9.23%
6M Performance:
+56.78%
1Y Performance:
+0.45%
Zynex Inc Stock (ZYXI) Company Profile
Name
Zynex Inc
Sector
Industry
Phone
303-703-4906
Address
9555 Maroon Circle, Englewood, CO
Zynex Inc Stock (ZYXI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Feb-28-22 | Reiterated | B. Riley Securities | Buy |
Jul-16-21 | Upgrade | B. Riley Securities | Neutral → Buy |
Mar-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
Feb-26-21 | Downgrade | B. Riley Securities | Buy → Neutral |
Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-28-21 | Downgrade | Northland Capital | Outperform → Market Perform |
Sep-14-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Sep-09-20 | Upgrade | Northland Capital | Market Perform → Outperform |
Jul-29-20 | Upgrade | B. Riley FBR | Neutral → Buy |
Jul-20-20 | Initiated | Piper Sandler | Overweight |
Jul-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
Jul-10-20 | Reiterated | H.C. Wainwright | Neutral |
Jun-16-20 | Downgrade | Northland Capital | Outperform → Market Perform |
May-19-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Apr-01-20 | Initiated | Northland Capital | Outperform |
Sep-23-19 | Initiated | H.C. Wainwright | Buy |
View All
Zynex Inc Stock (ZYXI) Latest News
Zynex Inc Stock (ZYXI) Financials Data
Zynex Inc (ZYXI) Revenue 2024
ZYXI reported a revenue (TTM) of $184.32 million for the quarter ending December 31, 2023, a +16.54% rise year-over-year.
Zynex Inc (ZYXI) Net Income 2024
ZYXI net income (TTM) was $9.73 million for the quarter ending December 31, 2023, a -42.91% decrease year-over-year.
Zynex Inc (ZYXI) Cash Flow 2024
ZYXI recorded a free cash flow (TTM) of $16.55 million for the quarter ending December 31, 2023, a +24.17% increase year-over-year.
Zynex Inc (ZYXI) Earnings per Share 2024
ZYXI earnings per share (TTM) was $0.26 for the quarter ending December 31, 2023, a -40.91% decline year-over-year.
About Zynex Inc
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also distributes electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct and independent sales representatives primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Cap:
|
Volume (24h):